Entrada Therapeutics advances ENTR-601-44 Phase 1/2 DMD trial to 18 mg/kg Cohort 3 after DMC review
TRDA•Entrada Therapeutics advanced its ELEVATE-44-201 trial to Cohort 3 at the 18 mg/kg dose after a committee reviewed safety and drug-behavior data from eight Cohort 2 participants. Cohort 1 open-label results are expected by year-end 2026, with Cohort 2 data scheduled for Q1 2027.
1. Trial advances dose
Entrada Therapeutics moved its ELEVATE-44-201 study into Cohort 3 at the 18 mg/kg dose following a safety committee review of available safety and drug-behavior data from eight Cohort 2 participants. The trial is evaluating ENTR-601-44 in Duchenne muscular dystrophy patients with mutations suitable for exon 44 skipping.
2. Data timing
Cohort 1 open-label results are expected by year-end 2026, and Cohort 2 data are scheduled for Q1 2027.
